116850-44-3
116850-44-3
Chemical Structure
MDL-27531
- CAS No.: 116850-44-3
- Formula:C10H11N3O2S
- Molecular Weight:237.28
InChIKey: DPGDRICHXKQXEN-UHFFFAOYSA-N
SMILES: O=S(=O)(C1=NN=C(C=2C=CC=CC2)N1C)C
Biological Activity: MDL-27531 acts functionally like a glycine agonist. MDL-27531 selectively reduces hindlimb contractions. MDL-27531 selectively reverses strychnine-induced seizures in mice. MDL-27531 inhibits pentylenetetrazol-induced seizures with an ED50 of 55 mg/kg. MDL-27531 promotes the binding of benzodiazepine antagonist Ro 15-1788 to cerebral cortex of mice without changing GABA levels. MDL-27531 can be studied in research on reflex control dysfunction[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MDL-27531 | MDL-27531 acts functionally like a glycine agonist. MDL-27531 selectively reduces hindlimb contractions. MDL-27531 selectively reverses strychnine-induced seizures in mice. MDL-27531 inhibits pentylenetetrazol-induced seizures with an ED50 of 55 mg/kg. MDL-27531 promotes the binding of benzodiazepine antagonist Ro 15-1788 to cerebral cortex of mice without changing GABA levels. MDL-27531 can be studied in research on reflex control dysfunction. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kehne, J. H., et al., (1992). MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neuroscience letters, 147(1), 101–105. [Content Brief]
- [2]. Kehne, J. H., et al., (1992). MDL 27,531 selectively reverses strychnine-induced seizures in mice. British journal of pharmacology, 106(4), 910–916. [Content Brief]
